| Overview |
| bs-6406R |
| CESK1 Polyclonal Antibody |
| WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CESK1 |
| 509-557/557 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 150160 |
| Cytoplasm |
| CCT8L2; KCNMB3L; T complex protein 1; CESK1; chaperonin containing TCP1, subunit 8 theta-like 2; Putative T-complex protein 1 subunit theta-like 2; T complex protein 1; chaperonin containing TCP1, subunit 8 theta-like 2; TCPQM_HUMAN. |
| CESK1, also known as CCT8L2 (chaperonin containing TCP1, subunit 8 theta-like 2), is a 557 amino acid protein that localizes to the cytoplasm and is thought to function as a molecular chaperone, possibly assisting protein folding after ATP hydrolysis. CESK1 belongs to the TCP-1 chaperonin family and is encoded by a gene which maps to human chromosome 22. Mutations in several of the genes that map to chromosome 22 are involved in the development of Phelan-McDermid syndrome, neurofibromatosis type 2, autism and schizophrenia. Additionally, translocations between chromosomes 9 and 22 may lead to the formation of the Philadelphia chromosome and the subsequent production of the novel fusion protein Bcr-Abl, a potent cell proliferation activator found in several types of leukemias. |
| Application Dilution |
| WB |
1:300-5000 |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz